Cardiac rehabilitation in children and adolescents with long QT syndrome: the RYTHMO’FIT pilot study

Table 1 Population characteristics

Patient number	Age (years)	Sex	Type of LQTS	Genetic mutation	Diagnosis	QTc interval (ms)	Clinical background before rehabilitation	Medication	LQTS -score diagnosis^a
#1	12	Male	LQT1	KCNQ1	Cardiac symptoms	440	Asymptomatic	Nadolol (40 mg daily)	1
#2	9	Male	LQT1	KCNQ1	Cardiac symptoms	497	Asymptomatic	Nadolol (40 mg daily)	5
#3	11	Male	LQT2	KCNH2	Prenatal genetic screening after known causal familial mutation	525	Bradycardia	Nadolol (50 mg daily)	5
#4	17	Male	LQT2	KCNH2	Cardiac symptoms	476	Syncope	Nadolol (80 mg daily)	4.5
#5	9	Female	LQT2	KCNH2	Genetic after known causal familial mutation	536	Refractory ventricular arrhythmia, ICD, cardiac sympathetic denervation	Nadolol (100 mg daily)	8
#6	13	Male	LQT1	KCNQ1	Incidental findings	466	Asymptomatic	Nadolol (70 mg daily)	2
#7	10	Male	LQT1	KCNQ1	Genetic after known causal familial mutation	423	Asymptomatic	Nadolol (40 mg daily)	1.5
#8	15	Male	LQT2	KCNH2	Genetic after known causal familial mutation	424	Syncope, implantable leadless cardiac monitor (REVEAL®)	Nadolol (40 mg daily)	1

LQTS Long QT syndrome. ICD Implantable cardioverter-defibrillator, QTc Corrected QT interval
^aSchwartz-score diagnostic criteria for long QT syndrome

ISSN: 2052-1847